Difference between revisions of "Office for Life Sciences"
| Line 8: | Line 8: | ||
The BMJ article describes other measures outlined in the blueprint, including | The BMJ article describes other measures outlined in the blueprint, including | ||
| − | :a strategic health authority delivery group to improve the uptake of innovative drugs and technologies. It will also be charged with improving the "engagement between industry and the NHS." David Nicholson, chief executive of the NHS, will review incentives, including payment by | + | :a strategic health authority delivery group to improve the uptake of innovative drugs and technologies. It will also be charged with improving the "engagement between industry and the NHS." David Nicholson, chief executive of the NHS, will review incentives, including payment by results, to accelerate the uptake of medical technologies.<ref>Deborah Cohen, [http://www.bmj.com/cgi/content/extract/339/jul15_3/b2887 Innovative drugs will bypass NICE approval process to build cost effective data], BMJ 2009;339:b2887, 15 July 2009 (subscription req'd to view full article)</ref> |
| − | results, to accelerate the uptake of medical technologies.<ref>Deborah Cohen, [http://www.bmj.com/cgi/content/extract/339/jul15_3/b2887 Innovative drugs will bypass NICE approval process to build cost effective data], BMJ 2009;339:b2887, 15 July 2009 (subscription req'd to view full article)</ref> | ||
==Affiliations== | ==Affiliations== | ||
Revision as of 14:34, 20 July 2009
The Office for Life Sciences (OLS), led by Lord Drayson, minister for science and innovation and founder of a biotech company, was set up in 2009 to develop measures to "improve the operating environment for UK life science companies".[1]
The OLS, in collaboration with representatives of the life sciences industry, academia, the NHS, and several government departments over a six month period, set up an initiative called The Life Sciences Blueprint, which, according to an article in the BMJ, has been described by representatives of different life science industries as a "major milestone."[2]
The BMJ article states that the Life Sciences Blueprint has come up with the idea of fast-tracking new drugs so that they do not have to go through the usual approvals process of the National Institute for Health and Clinical Excellence (NICE):
- Innovative drugs will be approved for NHS use without having first gone through the appraisal process of the National Institute for Health and Clinical Excellence (NICE), as part of a drive to stimulate the United Kingdom’s life sciences industry.[3]
The BMJ article describes other measures outlined in the blueprint, including
- a strategic health authority delivery group to improve the uptake of innovative drugs and technologies. It will also be charged with improving the "engagement between industry and the NHS." David Nicholson, chief executive of the NHS, will review incentives, including payment by results, to accelerate the uptake of medical technologies.[4]
Contents
Affiliations
Funding
Contact
- Address:
- ...
- ...
- ...
- ...
- Phone:
- ...
- Email:
- ...
- Website:
- ...
Resources
Notes
- ↑ Deborah Cohen, Innovative drugs will bypass NICE approval process to build cost effective data, BMJ 2009;339:b2887, 15 July 2009 (subscription req'd to view full article)
- ↑ Deborah Cohen, Innovative drugs will bypass NICE approval process to build cost effective data, BMJ 2009;339:b2887, 15 July 2009 (subscription req'd to view full article)
- ↑ Deborah Cohen, Innovative drugs will bypass NICE approval process to build cost effective data, BMJ 2009;339:b2887, 15 July 2009 (subscription req'd to view full article)
- ↑ Deborah Cohen, Innovative drugs will bypass NICE approval process to build cost effective data, BMJ 2009;339:b2887, 15 July 2009 (subscription req'd to view full article)
